ABSTRAm. Children with inborn errors of urea synthesis who survive neonatal hyperammonemic coma commonly exhibit cognitive deficits and neurologic abnormalities. Yet, there is evidence that ammonia is not the only neurotoxin. Hyperammonemia appears to induce a number of neurochemical alterations. In rodent models of hyperammonemia, uptake of L-tryptophan into brain is increased. It has been reported that in an experimental rat model of hepatic encephalopathy, in the ammonium acetate-injected rat, and in patients with hepatic failure and inborn errors of ammonia metabolism, quinolinate, a tryptophan metabolite, is increased. Elevations in quinolinate are of particular concern, as quinolinate could excessively activate the Nmethyl-maspartate subclass of excitatory amino acid receptors, thereby causing selective neuronal necrosis. We sought to identify an animal model that would replicate the increases in quinolinate that have been associated with hyperammonemia in humans. Levels of quinolinate were measured in hyperammonemic urease-infused rats and ammonium acetate-injected rats. In the urease-infused rat, brain tryptophan was doubled, and serotonin and its metabolite 5-hydroxyindoleacetic acid were significantly increased. Yet, despite the increase in tryptophan and evidence for increased metabolism of tryptophan to serotonin, there were no obsewed increases of quinolinate in brain, cerebrospinal fluid, or plasma. In the ammonium acetateinjected rat, significant increases of 5-hydroxyindoleacetic acid in cerebral cortex were also observed, but quinolinate did not change in cerebrospinal fluid or cerebral cortex. In summary, we were unable to demonstrate an increase of quinolinate in brain or cerebrospinal fluid in these rat models of hyperammonemia. (Pediatr Res 32: 483-488, 1992)
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Abbreviations
The most common causes of symptomatic hyperammonemia in children are congenital urea cycle disorders and organic acidemias. Affected children present with episodes of vomiting, lethargy, and coma either in the newborn period or in early childhood, depending on the severity of the enzyme deficiency (I). Despite treatment, the majority of children have cognitive deficits and other neurologic impairments (2) . Although the mechanism of brain damage induced by hyperammonemia is not clear, it is known that the degree of brain damage correlates with the duration of hyperammonemic coma rather than peak plasma ammonia level (2) , suggesting that ammonia may be acting through a secondary neurotoxin in a time-influenced fashion.
In certain animal models and humans with hyperammonemia induced by portal systemic encephalopathy, the level of the Trp metabolite, QUIN, has been found to be elevated in brain and CSF (3, 4) . This observation is noteworthy because QUIN is an agonist at the NMDA subclass of excitatory amino acid receptors. It is well documented that excessive activation of NMDA recep tors results in specific degeneration of the neurons that express these receptors (5, 6) .
It has been reported previously that children with urea cycle disorders have increased levels of Trp and the serotonin metabolite 5-HIAA in CSF and that this elevation is associated with behavioral alterations, such as decreased food intake and altered sleep patterns (7, 8) . Because Trp is a precursor for both 5-HIAA and QUIN (Fig. I) , we hypothesized that QUIN might be elevated in congenital hyperammonemias, as it is in portal systemic encephalopathy. In fact, we have documented increases of QUIN in CSF of children with congenital hyperammonemia (1 1). In this study, we attempted to provoke elevations in QUIN in two animal models of acute hyperammonemia: the urease-infused rat (12) and the ammonium acetate-injected rat. An osmotic minipump (Alzet 2001, Alza, Palo Alto, CA) was then implanted intraperitoneally under halothane or pentobarbital anesthesia. The minipump contained Jackbean urease (type VII, Sigma Chemical Co., St. Louis, MO) in sterile NaCl 0.9%, providing an infusion rate of 50 pM units/100 g body weight/d (1 pM unit is the amount of enzyme required to produce 1 pmol of NH3 per min from urea at pH 7.0 and at 25'C). A paired group of animals received sham operations. After surgery, the animals were returned to the complete amino acid mix.
MATERIALS A N D METHODS

CSF
In the first study, the animals were killed 12, 24, or 48 h after implantation to determine the timed effect of urease on amino acids, biogenic amines, and QUIN. The animals were decapitated in a nonfasting state, and the brains were dissected within 2 min on a cooled plate (14). The cortex of one hemisection was dissected for analysis of QUIN and the other hemisphere for biogenic amines and amino acids. All brain samples were stored at -70'C until the analyses were performed.
In the second study, animals were given an intraperitoneal injection of Trp (50 or 200 mg/kg) or saline 46 h after urease or sham implantation. Two h later blood, CSF, and brain tissue were obtained for analyses.
In the third study, animals received intraperitoneal injections of ammonium acetate (7 mmol/kg) or an equivalent volume (1 mL/kg) of sodium acetate or saline (0.9%). Solutions were made up in sterile saline and neutralized. CSF, blood, and brain tissue were obtained for analyses at 1 h after injection with ammonium acetate, sodium acetate, or saline. CSF samples were obtained from the cisterna magna 10 min after the animals were anesthetized with pentobarbital (50 mglkg) (I 5). All animal experimentation was performed in accordance with the highest possible standards of humane care and was approved by the Institutional Animal Care and Use Committee.
Biochemical Measures. Ammonium, amino acids, and biogenic amines. Before the rats were killed, heparinized blood was obtained by tail vein puncture. To prevent the generation of ammonia in vilro, the blood was precipitated with perchloric acid and centrifuged, and the supernatant was neutralized with KOH (16). After centrifugation, the supernatants were assayed for ammonium by a microfluorometric adaptation of a glutamate dehydrogenase method (12, 17). The brain tissues were homogenized (diluted 15) in a 0. l N sodium acetate buffer, pH 4.95. Amino acids in brain were measured after precipitation with 5% sulfosalicylic acid by automated ion exchange chromatography using a Beckman 6300 high pressure amino acid analyzer. For all studies except those presented in Table I , Trp was measured separately using an adaptation of an HPLC method with fluorometric detection using a Kratos flow-through fluorometer (Kratos Analytical Instruments, Ramsey, NJ) with a 254-nm excitation filter and 340-nm emission cutoff filter and an FSA 113 excitation lamp (Kratos Analytical Instruments) (18). The mobile phase consisted of a sodium acetate (50 mM) with disodium EDTA (50 pM) adjusted to pH 3 with phosphoric acid. Acetonitrile was added to a 8% final concentration. The flow rate was 1.0 mL/min. For the results presented in Table 1 , a McPherson FL-750 fluorometer set at 301 nm excitation with a 320-nm emission cutoff filter was used to measure Trp.
Biogenic amines and 3-hydroxykynurenine in brain were determined by an adaptation of a reverse phase HPLC method with electrochemical detection (ESA EC detector, Coulochem model 5100A, ESA, Bedford, MA) set at 0.45 V and a C18 reverse phase column (Brownlee Labs, Santa Clara, CA) (19). The mobile phase consisted of sodium acetate (50 mM), disodium EDTA (0.05 mM), and heptane sulfonate (Kodak) 2 mM, which was adjusted to pH 4 with phosphoric acid. Acetonitrile was added to a 6% final concentration. The flow rate was 1.0 mL/min. Brain tissue (diluted 1:20) was homogenized in a 0.1 N sodium acetate buffer, pH 4.95. Ascorbate oxidase (1 700 units/ mg, Sigma Chemical Co.) 6.7 pg/mL was added to the homogenates to eliminate the ascorbate front.
Quinolinic acid. QUIN measurements were made in a blinded fashion by one investigator (M.P.H.) using electron capture negative chemical ionization mass spectrometry and gas chromatography (20, 2 1). The high sensitivity of this method (minimum detectability of s 50 fg) allows quantification of QUIN at a signal to noise ratio of >20: 1, without the need for pooling of brain samples from different animals. QUIN and ["0]-QUIN were detected as the intact molecular anion rather than a low molecular weight fragment. Accuracy was obtained with [180]-QUIN as internal standard rather than structural isomers or chemical analogs of QUIN. ["0]-QUIN is chemically identical to QUIN, elutes from the chromatography system at the same time as QUIN, and has a small mass displacement that is sufticient to avoid the need to correct for naturally occurring isotopes. Samples or individual brain areas from each experiment were run within the same assay with a standard curve. The results presented in Table 2 were obtained by the original method (20, 2 I ) and a Kratos MS-80 magnetic sector mass spectrometer. The remaining results were obtained with the following modifications using a Hewlett-Packard 5988A mass spectrometer (HewlettPackard Co., Palo Alto, CA). Brain samples were placed in preweighted 1.5-mL polypropylene tubes, frozen in dry ice, and reweighed. Brain samples were sonicated in I mL of 3 M hydrochloric acid containing 9 pmol of ["OJ-QUIN and centrifuged, and 800 pL of the supernatant were mixed with 1 mL of water. QUIN standards (0-25 ng) were dissolved in 800 pL of water and mixed with the same hydrochloric acid/[lnO]-QUIN solution. Brain samples and standards were washed with 3 mL of chloroform, and the aqueous layer was collected. CSF (50 pL), plasma (10 pL), and QUIN standards dissolved in water (50 or 10 pL) were mixed with deionized water containing 9 pmol of ['"I-QUIN. All samples were freeze-dried overnight. QUIN and [180]-QUIN were esterified to their dihexafluoroisopropanol esters with complete retention of the isotope and extracted into 300-400 pL of heptane over 250 pL of water. Heptane extracts (1-2 pL) were injected directly into a 1 m x 0.53 mm inner diameter fused silica precolumn at 80°C attached to a 15 x 0.25 mm inner diameter DB-5 analytical capillary column, run isothermal at 1 14°C with helium as carrier gas. Transfer line and ion source were set at 175'C with methane as reagent gas at 0.5 mm Hg. QUIN and ['"OI-QUIN were monitored at m/z 467 and 47 1, respectively, and quantified as peak areas. Normal values for brain QUIN concentrations using this method consistently give brain QUIN concentrations substantially lower than those reported for the rat as determined by the electron capture mass Table 4 ) and for the analysis of QUIN (fmol/mg of tissue). Values represent the mean of at least six independent observations. The overall variance is given. ANOVA, analysis of variance.
Statistical Analyses. Sample size determinations were based on the reported variance for the measurement of QUIN (see above) and the previous observation that cortical QUIN was elevated 70% in hepatic encephalopathy and 60% in ammonium acetate-injected rats (4). This would indicate at least a 2-SD elevation. Sample sizes used in this study of five to eight per group yield a power of 80-95% for the detection of this difference with a = 0.05 (two-tailed t test). The data presented in Table 3 were compared by analysis of variance using SAS (SAS Institute, Inc., Cay, NC); the other data were compared by analysis of variance using a Statview 5 12+ on an Apple Macintosh.
RESULTS
Time course of urease. Because the neurologic effects of hyperammonemia appear to be related to its duration, the effects of urease infusion on the levels of biogenic amines and amino acids were examined over time. Table 3 summarizes the changes in biogenic amines, Trp, and QUIN in cortex during the 48 h after urease infusion. Plasma ammonium levels increased 7-fold within 12 h (normal levels were 193 pM), 4.5-fold at 24 h, and 3.0-fold at 48 h (mean of six observations at each time point, data not shown). From 12 to 48 h, levels of Trp in urease-infused rats were 100% elevated compared to sham controls. There were 50% increases in 5-HIAA. Serotonin levels were significantly elevated at 48 h. Urease infusion had no significant effects on QUIN, norepinephrine, or dopamine. Cortical amino acids were also measured (Table 3 ). In the urease-infused animals, glutamine was most elevated (ffold, p < 0.0001). There were also significant increases in proline, tyrosine, phenylalanine, histidine, lysine, and arginine. No significant changes were observed in other amino acids.
Efect of urease and Trp infusion on biogenic amines, Trp, and QUIN. In an attempt to accentuate possible differences in Trp metabolism in the urease-infused rat, either Trp (200 mg/kg) or saline was injected intraperitoneally 46 h after implanting the urease-containing pump. The levels of brain biogenic amines and QUIN were measured in animals killed 2 h after injection of Trp. Table 4 shows that both free and total Trp in plasma increased 3-to 4-fold after Trp injection, but that there was no difference between urease-infused and sham animals. As observed in the first study (Table 3) , urease infusion caused increases in Trp, 5-HIAA, and serotonin in cortex (Table 4) . Norepinephrine was not affected. Although Trp infusion resulted in further increases of Trp and 5-HIAA, serotonin and norepinephrine levels did not change (Table 4) . ZHydroxykynurenine, one of the intermediates from Trp to QUIN, was elevated after Trp infusion. There were no significant statistical interactions between Trp and urease infusion. QUIN was measured in multiple brain regions of these animals ( Table 2) . Although Trp infusion resulted in at least 3-fold increases of QUIN in all regions in both urease-infused rats and sham controls ( p c 0.01), urease infusion alone had no effect on QUIN levels. In fact, Trp(+)/urease-infused animals had lower levels of QUIN in striatum, thalamus, and parietal cortex than did the Trp(+)/sham animals ( p < 0.05). There was significant interaction between urease infusion and Trp injections in both parietal cortex and striatum.
Levels of 5-HIM and QUIN in CSF. The levels of QUIN in plasma are 8-fold higher than the levels of QUIN in brain tissue (20). The negative findings of our study, coupled with the observation of high QUIN in plasma, prompted the concern that the blood left in brain tissue masked increases of QUIN. To control for this theoretical contamination, another group of animals was injected with Trp (50 mg/kg) 46 h after implant of the ureasecontaining pumps. Two h later, the animals were anesthetized and CSF was removed. The levels of 5-HIAA and QUIN in CSF and the levels of QUIN in plasma were measured (Table 5) . Even though Trp injection resulted in a marked increase in the concentration of QUIN in both CSF and plasma, urease had no effect on QUIN values in CSF. As was seen with brain tissue, urease infusion increased the levels of 5-HIAA in CSF. There QUIN in brain and CSF of animals injected with ammonium acetate. In a previous study, Moroni et al. (4) reported increased cortical QUIN levels and 5-HIAA after ammonium acetate injection. In our final study, rats were injected with ammonium acetate to stimulate an increase in QUIN. Plasma, CSF, and cortical tissue were obtained 1 h after injection with ammonium acetate (7 mmol/kg) ( Table 1) . At 1 h after injection, plasma ammonium was elevated to twice that of control (control = 140 pM, p < 0.05). As seen in the urease-infused rat, ammonium acetate injection caused a significant increase in brain 5-HIAA, but had no effect on QUIN levels in plasma, CSF, or cortex.
DISCUSSION
Trp is metabolized to both serotonin and QUIN (Fig. 1) . QUIN has agonist activity at the NMDA subclass of excitatory amino acid receptors (for reviews see 5, 6) . Excessive activation of these receptors by QUIN or other NMDA receptor agonists results in neurodegeneration. These receptors have been associated with such normal brain processes as regulation of synaptogenesis and long term potentiation (for reviews see 5, 6) . In a portocaval shunted rat, Moroni et al. (4) documented increased levels of QUIN in cerebral cortex (1.7-fold), but no changes in hippocampus, caudate, or brainstem. After ammonium acetate injection, this same group observed increased QUIN (1.6-fold) in cerebral cortex. The levels of QUIN in blood and CSF were not determined in either study. We have documented 2-to 10-fold increases of QUIN in CSF of comatose children and 2-to 4-fold increases of QUIN in CSF of clinically stable children with congenital hyperammonemia (1 1). Previous studies have also documented increased levels of the serotonin metabolite, 5-HIAA, in CSF and/or brain of children with congenital hyperammonemia, adults with hepatic encephalopathy, and animal models of these diseases (7, 8, (22) (23) (24) . Some studies (9, 10) suggest that augmented transport of Trp into the CNS leads to this increase in serotonin turnover (Fig. 1) .
The goal of the present studies was to examine the relationship between plasma ammonium levels and QUIN in brain and CSF of rat models of hyperammonemia. We chose animal models that simulated urea cycle disorders in causing hyperammonemia in the absence of liver damage. Previous studies have docu- Urease-infused and sham-operated control animals were injected with Trp (200 mg/kg intraperitoneally), designated Trp(+), or saline, designated TIP(-). 46 h after surgery. At 48 h after surgery, blood and CSF were harvested for analysis of QUlN and 5-HIAA. Values represent the mean of six independent observations. The overall variance is given. ANOVA, analysis of variance.
mented the use of urease infusion as a model of congenital hyperammonemia (1 2). To maximize alterations in brain metabolism, the dose was doubled in the current studies. At this dose, there was a 20% mortality rate. Most animals experienced periods of ataxia and occasional tonicclonic seizures. The levels of brain Trp were approximately 2-fold elevated, and the levels of serotonin and 5-HIAA were significantly elevated (Table 3) . Despite large increases in the levels of Trp and some of its metabolites, we were unable to document an effect of urease on the levels of QUIN in frontal cortex (Table 3) , parietal cortex, striatum, thalamus, and hippocampus ( Table 2) .
The levels of QUIN observed in the current study are almost 50-fold lower than those previously reported by Moroni et al. (4) but are similar to those consistently reported by a coauthor of the present study (M.P.H.) (20, 21, 25, 26) . In more recent studies by Moroni et al. (27) , the levels of QUIN are only approximately 7-fold higher than those reported in the current study. The reason for these discrepancies is not clear, but it may be related to the fact that, in all of the studies by Heyes and the recent studies by Moroni et al. (27) , [180]-QUIN was used as an internal standard, and a structural analog of QUIN was used as an internal standard in the earlier studies of Moroni et al. (4) .
The maximum change in biogenic amines was observed at 48 h after implant. To capitalize on this, we explored the effects of urease infusion on the levels of brain QUIN at 48 h. Trp injections were combined with urease infusion in an attempt to accentuate changes in QUIN. At 46 h post implant, animals received injections of either Trp or saline and were killed 2 h later. Whereas the Trp injection resulted in a substantial increase in the levels of Trp, 5-HIAA, 3-hydroxykynurenine, and QUIN in cortex, the levels of QUIN were not elevated to a greater extent in the urease-infused animals than in the controls (Tables  2 and 4) .
We were concerned that, because the levels of QUIN are 8-fold higher in blood than in brain (20), it was possible that any changes in brain QUIN might have been masked by the presence of blood in brain tissue. To control for this, the effects of urease infusion combined with Trp injections on the levels of plasma QUIN, CSF QUIN, and CSF 5-HIAA were examined ( Table 5) . As observed in brain tissue, urease infusion elevated the levels of 5-HIAA in CSF, but had no effect on the levels of QUIN in CSF or plasma. L-Trp administration increased both plasma and CSF QUIN levels to the same degree in sham and urease-infused animals.
We then attempted to replicate the findings of increased QUIN in the brains of animals acutely injected with ammonium acetate (4) . As seen with the urease-infused animals, ammonium acetate injection elevated 5-HIAA levels in brain to levels above control but did not affect QUIN levels in either CSF or brain. This observation suggests that neither the synthesis of QUIN in brain nor the diffusion of QUIN across the blood brain bamer are increased by hyperammonemia. It is possible, however, that increases in QUIN may have been attenuated by increased catabolism by quinolinic acid phosphoribosyltransferase, the enzyme that metabolizes QUIN.
These data, together with our observations of increased QUIN in children with congenital hyperammonemia (1 l), suggest that the regulation of the synthesis or degradation of QUIN may be different in humans than in these rat models of hyperammonemia. A possible explanation for this discrepancy involves the regulation of indoleamine-2,3-dioxygenase, the first enzyme in the pathway for the conversion of Trp to QUIN (Fig. 1) . The
